{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:10:35Z","timestamp":1768432235230,"version":"3.49.0"},"reference-count":23,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2024,7,10]]},"DOI":"10.1253\/circrep.cr-24-0017","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T22:12:06Z","timestamp":1719612726000},"page":"248-254","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Benefit of Sacubitril\/Valsartan for Hypertensive Patients in Daily Practice and Predictors of Its Antihypertensive Effect"],"prefix":"10.1253","volume":"6","author":[{"given":"Takeshi","family":"Horio","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Ishikiriseiki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Iwashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kansai Medical University Kori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshiyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Daito Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Metabolism, Ishikiriseiki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Ishikiriseiki Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: Insights from hypertension and heart failure trials. <i>Eur Heart J<\/i> 2015; 36: 1967\u20131973.","DOI":"10.1093\/eurheartj\/ehv142"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lin DS, Wang TD, Buranakitjaroen P, Chen CH, Cheng HM, Chia YC, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe. <i>J Clin Hypertens<\/i> 2021; 23: 556\u2013567.","DOI":"10.1111\/jch.14120"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. <i>Hypertens Res<\/i> 2021; 44: 1239\u20131250.","DOI":"10.1038\/s41440-021-00706-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Long-term treatment with sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction: Open-label extension of the PARALLEL-HF Study. <i>Circ J<\/i> 2024; 88: 43\u201352.","DOI":"10.1253\/circj.CJ-23-0174"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril\/valsartan in Japanese patients with heart failure according to baseline systolic blood pressure: Results from a subgroup analysis of the PARALLEL-HF Study. <i>Circ J<\/i> 2024; 88: 53\u201361.","DOI":"10.1253\/circj.CJ-23-0349"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Imamura T, Kinugawa K. Implication of sacubitril\/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients. <i>Ann Palliat Med<\/i> 2022; 11: 2856\u20132861.","DOI":"10.21037\/apm-22-483"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sazawa K, Ohno K, Yamashita T, Ino S, Shibata S, Itoh T, et al. Effects of sacubitril\/valsartan on glycemic control in Japanese patients with heart failure and\/or hypertension. <i>Circ Rep<\/i> 2022; 4: 588\u2013594.","DOI":"10.1253\/circrep.CR-22-0109"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mitsuno R, Uchiyama K, Nakayama T, Takahashi R, Yoshimoto N, Yamaguchi S, et al. Comparison of the effects of angiotensin receptor-neprilysin inhibitors and thiazide diuretic\/renin-angiotensin system inhibitor combination therapy in hypertensive patients: A retrospective cohort study. <i>J Hum Hypertens<\/i> 2023; 37: 1049\u20131055.","DOI":"10.1038\/s41371-023-00851-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen CW, Zhang J. Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. <i>J Clin Hypertens<\/i> 2018; 20: 150\u2013158.","DOI":"10.1111\/jch.13153"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. <i>J Clin Hypertens<\/i> 2019; 21: 67\u201376.","DOI":"10.1111\/jch.13437"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: A randomized, double-blind, multicenter study. <i>Hypertens Res<\/i> 2022; 45: 824\u2013833.","DOI":"10.1038\/s41440-021-00819-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wu HX, Liu KK, Li BN, Liu S, Jin JC. Efficacy and safety of sacubitril\/valsartan in the treatment of middle-aged and elderly patients with hypertension: A systematic review and meta-analysis of randomized controlled trials. <i>Ann Palliat Med<\/i> 2022; 11: 1811\u20131825.","DOI":"10.21037\/apm-22-503"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Twenty-four-hour blood pressure-lowering efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: A post hoc analysis of data from a randomized, double-blind multicenter study. <i>J Am Heart Assoc<\/i> 2023; 12: e027612.","DOI":"10.1161\/JAHA.122.027612"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2019). <i>Hypertens Res<\/i> 2019; 42: 1235\u20131481.","DOI":"10.1038\/s41440-019-0284-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. <i>Am J Kidney Dis<\/i> 2009; 53: 982\u2013992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Li W, Gong M, Yu Q, Liu R, Chen K, Lv W, et al. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension. <i>J Clin Hypertens<\/i> 2022; 24: 449\u2013456.","DOI":"10.1111\/jch.14454"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Iwashima Y, Fukushima H, Horio T, Rai T, Ishimitsu T. Efficacy and safety of sacubitril\/valsartan after switching from azilsartan in hemodialysis patients with hypertension. <i>J Clin Hypertens<\/i> 2023; 25: 304\u2013308.","DOI":"10.1111\/jch.14635"},{"key":"18","unstructured":"18. Ye Q, Sheng Y, He X. Comparative analysis of sacubitril\/valsartan and losartan potassium in the treatment of hypertension: Efficacy, adverse reactions, and observations. <i>Am J Transl Res<\/i> 2023; 15: 5715\u20135722."},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Zhang S, Yin Z, Li ZF, Zhang WJ, Sui YG, Xu YL, et al. The effects of sacubitril\/valsartan compared to olmesartan on the blood pressure and glucolipid metabolism in DM patients with primary hypertension. <i>Cardiovasc Drugs Ther<\/i> 2023, doi:10.1007\/s10557-023-07509-1.","DOI":"10.1007\/s10557-023-07509-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kusaka H, Sueta D, Koibuchi N, Hasegawa Y, Nakagawa T, Lin B, et al. LCZ696, Angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. <i>Am J Hypertens<\/i> 2015; 28: 1409\u20131417.","DOI":"10.1093\/ajh\/hpv015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, et al. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. <i>Hypertension<\/i> 2017; 69: 32\u201341.","DOI":"10.1161\/HYPERTENSIONAHA.116.08484"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sharma AM, Schorr U, Oelkers W, Distler A. Effects of sodium salts on plasma renin activity and norepinephrine response to orthostasis in salt-sensitive normotensive subjects. <i>Am J Hypertens<\/i> 1993; 6: 780\u2013785.","DOI":"10.1093\/ajh\/6.9.780"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ishihara S, Hiramitsu S, Kanaoka K, Taki M, Nakagawa H, Ueda T, et al. New conversion formula between B-type natriuretic peptide and N-terminal-pro-B-type natriuretic peptide: Analysis from a multicenter study. <i>Circ J<\/i> 2022; 86: 2010\u20132018.","DOI":"10.1253\/circj.CJ-22-0032"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/6\/7\/6_CR-24-0017\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T03:28:25Z","timestamp":1720841305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/6\/7\/6_CR-24-0017\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-24-0017","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"article-number":"CR-24-0017"}}